



AVERAGE SALES PRICE (ASP)

FOR MEDICARE PART B — ESTABLISHED FOR FIRST-QUARTER 2019

STELARA® (ustekinumab) 45 mg/0.5 mL single-dose vial for subcutaneous injection

When **STELARA® (ustekinumab) 45 mg/0.5 mL single-dose vial for subcutaneous injection** is administered in a physician's office and covered under Medicare Part B, it is reimbursed based on ASP + 6%.¹ Drug reimbursement is currently subject to sequestration, which reduces the portion of the payment paid by Medicare (80%) by 2%.² As a result, the payment rate is effectively ASP + 4.3%.

- ASP is based on quarterly sales data provided by manufacturers³

$$\text{ASP} = \frac{\text{Gross Sales} - (\text{Discounts} + \text{Chargebacks} + \text{Rebates})}{\text{Total Number of Units Sold}}$$

- Manufacturers submit ASP data to the Centers for Medicare & Medicaid Services (CMS) by specific deadlines following the end of each quarterly period. CMS uses this data to determine the Medicare reimbursement rate for the subsequent quarter. This results in a two-quarter lag between the quarter in which the sales occur and the time when the sales are reflected in a revised reimbursement rate. For example, first-quarter sales become the basis for third-quarter reimbursement⁴

First-Quarter 2019 STELARA® Medicare Allowable⁵: 45 mg/0.5 mL single-dose vial

HCPSC CODE	SHORT DESCRIPTION	FIRST-QUARTER 2019 ASP RATE	NDC NUMBER
J3357 ⁵	ustekinumab sub cu inj, 1 mg ⁵	\$184.046 per 1 mg ⁵	57894-060-02 ⁶

Note: J3357 is reported per 1-mg unit. Medicare Allowable is based on ASP + 6% and is subject to adjustment under sequestration, which is functionally ASP + 4.3%.

STELARA®	# OF UNITS	FIRST-QUARTER 2019 MEDICARE ALLOWABLE
45 mg/0.5 mL single-dose vial	45	\$8282.07 per vial

Note: The Medicare Allowable rate is adjusted for sequestration, which is functionally ASP + 4.3%.

Before prescribing STELARA®, please read the full Prescribing Information and Medication Guide available at www.STELARAhcp.com. Provide the Medication Guide and Instructions for Use to your patients and encourage discussion.

The fact that a drug, device, procedure, or service is assigned a HCPCS code and a payment rate does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the program. Fiscal Intermediaries (FIs)/Medicare Administrative Contractors (MACs) determine whether a drug, device, procedure, or other service meets all program requirements for coverage.⁷

The information in this guide is provided to assist you in understanding the reimbursement process. It is intended to help providers in accurately obtaining reimbursement for healthcare services. It is not intended to increase or maximize reimbursement by any payer. We strongly suggest that you consult your payer organization with regard to local reimbursement policies. This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations, and policies concerning reimbursement are complex and updated frequently. While Janssen Biotech, Inc., has made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. Please consult with your counselor reimbursement specialist for any reimbursement or billing questions. Similarly, all Current Procedural Terminology (CPT®)* and Healthcare Common Procedural Coding System (HCPCS) billing codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Janssen Biotech, Inc., that these codes will be appropriate or that reimbursement will be made.

*CPT® is a registered trademark of the American Medical Association.

References: 1. 42 CFR § 414.904. 2. 2 USC § 901a(6). 3. 42 CFR § 414.804. 4. 42 USC § 1395w-3a. 5. Centers for Medicare & Medicaid Services. 2019 ASP Drug Pricing Files. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles.html>. Accessed December 7, 2018. 6. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 7. Centers for Medicare & Medicaid Services. CMS Manual System, Pub 100-04 Medicare Claims Processing. <http://www.cms.gov/transmittals/downloads/R1139CP.pdf>. Accessed December 7, 2018.

